MESOBLAST LTD

1.650

+0.0301.85%

Volume:3.42M

Turnover:5.56M

Market Cap:2.10B

PE:-11.48

High:1.660

Open:1.600

Low:1.575

Close:1.620

Loading ...

Overview Company News Filings

Concept

Novel Coronavirus Treatment-0.31%

Pharmaceutical Companies-0.75%

Capital Flow

Inflow:

Outflow:

News

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/MSB.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MSB.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","market":"AU","secType":"STK","nameCN":"MESOBLAST LTD","latestPrice":1.65,"timestamp":1744870320000,"preClose":1.62,"halted":0,"volume":3420923,"delay":0,"nameEN":"MESOBLAST LTD","floatShares":777083698,"shares":1269984284,"eps":-0.14378350579728214,"marketStatus":"Not Yet Opened","change":0.03,"latestTime":"04-17 16:12:00 AEST","open":1.6,"high":1.66,"low":1.575,"amount":5557931,"amplitude":0.052469,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.14378350579728214,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745280000000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":1.62,"openAndCloseTimeList":[[1744848000000,1744869600000]],"volumeRatio":0.40172028459109826,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","floatShares":777083698,"roa":"-4.85%","roe":"-21.31%","lyrEps":-0.138918,"volumeRatio":0.40172028459109826,"shares":1269984284,"dividePrice":0,"high":1.66,"amplitude":0.052469,"preClose":1.62,"low":1.575,"week52Low":0.76,"pbRate":"2.92","psRate":"237.15","week52High":3.37,"institutionHeld":0,"latestPrice":1.65,"eps":-0.14378350579728214,"divideRate":0,"volume":3420923,"delay":0,"ttmEps":-0.14378350579728214,"open":1.6,"prevYearClose":3.1,"prevWeekClose":1.65,"prevMonthClose":1.96,"prevQuarterClose":1.96,"fiveDayClose":1.735,"twentyDayClose":2.2,"sixtyDayClose":2.75},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/MSB.AU\",params:#limit:6,delay:false,,,undefined,":[{"market":"AU","name":"Novel Coronavirus Treatment","bkCode":"BK7501","id":"package_au_concept_xgzlg","changeRate":-0.003062},{"market":"AU","name":"Pharmaceutical Companies","bkCode":"BK7508","id":"package_au_concept_yyswg","changeRate":-0.007524}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MSB.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2528732243","title":"Mesoblast Expands Insurance Coverage for Ryoncil to 104 Million Lives in US","url":"https://stock-news.laohu8.com/highlight/detail?id=2528732243","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528732243?lang=en_us&edition=fundamental","pubTime":"2025-04-17 12:23","pubTimestamp":1744863798,"startTime":"0","endTime":"0","summary":"Mesoblast  expanded its coverage for Ryoncil to 104 million US government- and private-insured lives, according to a Thursday filing with the Australian bourse.Ryoncil is approved by the US Food and Drug Administration for mesenchymal stromal cell therapy.It is the only approved therapy for steroid-refractory acute graft versus host disease  in children aged two months and older, a separate filing showed.Mesoblast's shares were up nearly 2% in recent trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","MESO","MSB.AU","BK4139","BK7501"],"gpt_icon":0},{"id":"2528842107","title":"Mesoblast Extends Payer Coverage For Ryoncil® to Over 100 Million US Lives","url":"https://stock-news.laohu8.com/highlight/detail?id=2528842107","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528842107?lang=en_us&edition=fundamental","pubTime":"2025-04-17 09:20","pubTimestamp":1744852800,"startTime":"0","endTime":"0","summary":"NEW YORK, April 16, 2025  -- Mesoblast , global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has continued to expand coverage for Ryoncil , the first mesenchymal stromal cell  therapy approved by U.S. Food and Drug Administration  for any indication, to 104 million US lives insured by government and commercial payers.Mesoblast’s RYONCIL  for the treatment of steroid-refractory acute graft versus host disease  in pediatric patients 2 months and older is the first FDA approved mesenchymal stromal cell  therapy. Please see the full Prescribing Information at www.ryoncil.com.About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications are expected to provide commercia","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mesoblast-extends-payer-coverage-ryoncil-012000537.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MSB.AU","BK4139","BK4575","MSC","BK4150","MSB","MESO","BK4006"],"gpt_icon":0},{"id":"2527186297","title":"Here are the top 10 ASX 200 shares today","url":"https://stock-news.laohu8.com/highlight/detail?id=2527186297","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527186297?lang=en_us&edition=fundamental","pubTime":"2025-04-14 15:01","pubTimestamp":1744614107,"startTime":"0","endTime":"0","summary":"It was a flying start to the trading week for the S&P/ASX 200 Index (ASX: XJO) this Monday. After a rough end to last week, investors came back from the weekend with a spring in their steps. By the ti","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/14/here-are-the-top-10-asx-200-shares-today-14-april-2025/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["SMR.AU","BK7067","XJO.AU","BK7504","PME.AU","NEU.AU","PNV.AU","BK7501","BK7129","BK7016","WHC.AU","BK7507","CU6.AU","SDR.AU","BK7083","MSB.AU","BK7096","BK7126","BK7094","BK7062","PNI.AU","BK7095","BK7508","MIN.AU"],"gpt_icon":0},{"id":"2525381656","title":"Here are the ASX 200 shares leading Tuesday's market rebound","url":"https://stock-news.laohu8.com/highlight/detail?id=2525381656","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525381656?lang=en_us&edition=fundamental","pubTime":"2025-04-08 10:07","pubTimestamp":1744078054,"startTime":"0","endTime":"0","summary":"S&P/ASX 200 Index (ASX: XJO) shares are rebounding, currently up 1.4% to 7,449.1 points at the time of writing.  Today's rebound follows a horror day on the market yesterday.  ASX 200 shares fell to t","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/08/here-are-the-asx-200-shares-leading-tuesdays-market-rebound/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7016","BK7067","BK7507","BK7051","XJO.AU","BK7501","PNV.AU","BK7095","LTR.AU","CSC.AU","PME.AU","BK7093","ZIP.AU","BK7158","AOV.AU","BK7504","MSB.AU","BK7110","BK7508","XYZ.AU","BK7083","BK7094","360.AU","WHC.AU","BK7126"],"gpt_icon":0}],"pageSize":4,"totalPage":42,"pageCount":1,"totalSize":165,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MSB.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-26","symbol":"MSB.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MSB.AU\",market:\"AU\",,,undefined,":[]}}